LifeSemantics Applies for Product Approval of Blood Pressure Prediction AI Solution

Medical AI company LifeSemantics announced on the 11th that it has completed the application for product approval of the blood pressure prediction AI solution Canofy MD BPAI to the Ministry of Food and Drug Safety.

Canofy MD BPAI was developed through the Doctor Answer 2.0 project led by the Ministry of Science and ICT and the National IT Industry Promotion Agency (NIPA). It is a medical AI solution that predicts blood pressure 1 to 4 weeks ahead based on clinical data when patients record their blood pressure at home via a mobile application (app) for 8 weeks.

Hypertension is a representative chronic disease that often goes unnoticed due to the lack of clear symptoms. If left unmanaged for a long time, it can lead to cardiovascular diseases such as stroke, requiring active management. However, the ‘white coat effect,’ where there is a difference between blood pressure measured in the clinic and outside the clinic, often occurs, increasing the importance of measuring and managing blood pressure in daily life.

Canofy MD BPAI goes beyond simple blood pressure measurement and recording by predicting future blood pressure trends, motivating patients to measure and manage their blood pressure themselves. Additionally, it provides information on risk levels and management appropriateness evaluations, which is expected to help medical staff manage and treat patients.

Hong Seung-yong, head of the Medical Device Business Division at LifeSemantics, said, “We are very pleased to showcase the results of the medical AI products we have been diligently developing,” and added, “We will focus on commercialization so that the product can be quickly utilized in medical settings once the approval application process is completed.”